Evotec stock at EUR 2.82 ahead of Xetra open: drug group slightly higher by 0.36 percent
Published on 10/26/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness model and market context
- Evotec develops medicines with partners through data-driven research.
- Germany's home-market benchmark is the DAX on October 26, 2026.
- Evotec stock trades pre-market at EUR 2.82 at 7:56 a.m. CET at Lang & Schwarz on October 26, 2026, 0.36 percent above the Xetra close of October 23, 2026.
Evotec develops medicines with partners through data-driven research. Evotec's Investor Relations materials describe the company's research and development activities. Evotec stock trades pre-market at EUR 2.82 at 7:56 a.m. CET at Lang & Schwarz on October 26, 2026, 0.36 percent above the Xetra close of October 23, 2026 (EUR 2.81).
Ahead of the Xetra open
The stock is EUR 0.01 above the Xetra close. The bid was EUR 2.79 and the ask EUR 2.85, a spread of 2.13 percent in pre-market trading. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Evotec stock.
Business and the trading day
Evotec combines strategic collaborations with technology fees, licenses, milestone payments and revenue sharing in its business model, according to its Investor Relations materials. Germany's home-market benchmark is the DAX on October 26, 2026. Market context: Market report DAX.
